Dataset for studies on engineered hydrocortisone for treating orthotropic colon cancer

Published: 9 July 2020| Version 2 | DOI: 10.17632/cvgvbn9hsg.2
Contributor:
Rajkumar Banerjee

Description

Hydrocortisone, the endogenous hormone for glucocorticoid receptor (GR) is chemically engineered which allowed it to form its self-assembly in aqueous solution using ethanol injection method. Engineered hydrocortisone in its molecular state exhibits its anticancer nature. Together with its unique surface positive charge and hydrophobic interior the self-assembled entity could carry therapeutic gene and drug to act as a composite therapeutic agent. As an altogether action it showed synergism in its action against orthotopic colon cancer in mouse. But, most importantly, the delivery was uniquely via GR expressed in cancer cells. Non-cancer cells or other, normal organs largely remained unperturbed. We also found that synergistic anticancer effect was mainly due to the GR-mediated drug sensitisation in cancer cells. Together, the system is an unique anticancer drug/gene delivery system which has the multi-modal ability to treat aggressive cancers such as colon cancer .

Files

Categories

Colon Cancer, Glucocorticoid Receptor, Gene Delivery, Targeted Therapeutic Agent, Sensitization

License